News

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...
Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...
SGR-1505 was designed using Schrödinger's computational platform at scale and was discovered approximately 10 months after the company started its MALT1 program. A Phase 1 study in patients with ...
In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in ...
Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...
Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...
Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued ...
New trial results reveal BGB-16673's promising safety and efficacy in treating relapsed CLL/SLL, showing significant ...
More information: Xubin Li et al, Large B cell lymphoma microenvironment archetype profiles, Cancer Cell (2025). DOI: 10.1016/j.ccell.2025.06.002 ...
GEO-CM04S1 demonstrated significantly enhanced T cell responses, specifically IFN-γ secretion and activation-induced markers (AIM+), compared to a matched cohort receiving an authorized mRNA vaccine.
Discover why BeOne Medicines (BEIGF) is a strong Buy with growth driven by Brukinsa, Tevimbra, and a promising oncology pipeline.